Clinical trial Recruiting at 1 site Interventional Ages 0 Days to 90 Days

Lactoferrin to help prevent infections in ventilated newborns

Official title: Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.

Run by Tanta University · NCT07255742 · Data updated 2026-11-12

This study tests whether giving lactoferrin to ventilated neonates can help prevent ventilator-associated pneumonia and related complications.

Quick facts

Study typeInterventional
Ages0 Days to 90 Days
SexAll
Enrollment120 (estimated)
SponsorTanta University
Academic / other
Locations1 site (Tanta)
StatusRecruiting
StartedAugust 1, 2025
Main results expectedNovember 1, 2026
Study endsNovember 1, 2026
Registry record updatedOctober 6, 2026
Trial IDNCT07255742 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Neonates requiring mechanical ventilation for an anticipated duration of at least 48 hours, without congenital lung/airway anomalies, major congenital heart disease, early onset sepsis, severe perinatal asphyxia, or other conditions preventing participation.

Probably not a fit

Patients with severe gastrointestinal pathology, known lactoferrin allergy, proven early sepsis at enrollment, or conditions interfering with participation may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial investigates the preventive use of lactoferrin in neonates who require mechanical ventilation. It compares lactoferrin to a control to see if it reduces the incidence of ventilator-associated pneumonia, sepsis, feeding intolerance, vomiting, constipation or diarrhea, and impacts duration of ventilation and hospital stay. The study targets critically ill neonates without major congenital conditions, and excludes those with early proven sepsis or significant gastrointestinal disease. Outcomes include both the primary effect on VAP and secondary effects on clinical course. Conducted at a neonatal intensive care unit in a university hospital setting, with the lead sponsor and no listed collaborators beyond the site.

Why it matters

Potential benefit: If successful, lactoferrin could reduce VAP and related complications, potentially shortening ventilation time and hospital stay for ventilated neonates.

How similar studies have gone: Prior studies in neonates have explored lactoferrin for infection prevention with mixed results; this trial adds randomized, controlled data for VAP prevention.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

neonates requiring mechanical ventilation.

Gestational age:

Expected need for mechanical ventilation for ≥ (48hours)

Exclusion Criteria:

Congenital anomalies of the lung or airway.

Major congenital heart disease.

Proven early-onset sepsis at enrollment.

Severe perinatal asphyxia (e.g., Apgar \< 3 at 5 minutes or seizures).

Known contraindication or allergy to lactoferrin.

Severe gastrointestinal pathology (e.g., NEC stage II or higher).

Any condition deemed by the clinical team to interfere with study participation.

Where it's running

  • Neonatal Intensive Care Unit, Tanta University Children's Hospital
    Tanta, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.